Metacognitive Interpersonal Therapy Across Transdiagnostic Eating Disorders, Including Underweight
Launched by GLORIA FIORAVANTI · Nov 15, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new type of therapy called Metacognitive Interpersonal Therapy for Eating Disorders (MIT-ED) to see if it helps people with various eating disorders, especially those who are underweight. The main goals are to find out if this therapy can improve symptoms of eating disorders, help with emotional issues like self-esteem and perfectionism, and reduce the chance that patients will drop out of treatment. Participants will be adults aged 18 and older who have an eating disorder and meet certain health criteria.
If you join the trial, you will go through an initial screening to make sure you qualify. If you do, you can expect to receive up to 40 therapy sessions over about 10 to 12 months. During this time, you will also take part in regular assessments to track your progress in managing eating disorder symptoms and emotional challenges. Researchers hope that positive findings from this trial will lead to larger studies to further explore the benefits of MIT-ED.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult outpatients (from age 18 years)
- • Having an Eating Disorder for which they required treatment
- • BMI between 17.5 and 40
- • Provision of informed consent
- Exclusion Criteria:
- • Receiving ongoing psychiatric, other psychotherapeutic treatment
- • Coexisting psychiatric disorders precludeing eating disorder-focused treatment or that requires specialized treatment: bipolar I, psychosis, alcohol or substance abuse, suicidality. PTSD is an exclusion criteria as long as its symptoms as prominent so to require a specialized empirically supported treatment
- • Intellectual disability
About Gloria Fioravanti
Gloria Fioravanti is a dedicated clinical trial sponsor specializing in the advancement of innovative therapies and treatments across various medical fields. With a strong commitment to enhancing patient care, the organization focuses on conducting high-quality, ethically-sound research that adheres to rigorous regulatory standards. Leveraging a team of experienced professionals, Gloria Fioravanti fosters collaborations with leading researchers and institutions to ensure the successful design and execution of clinical trials. The sponsor's mission is to translate scientific discoveries into safe and effective healthcare solutions, ultimately improving the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Verona, Italia, Italy
Patients applied
Trial Officials
Giancarlo Dimaggio
Study Chair
Centro di Terapia Metacognitiva Interpersonale, Roma
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported